NEJM: Phase III clinical trials have shown that Artju monoantigen significantly prolongs the survival of non-small cell lung cancer patients who express PD-L1.

Oct 6, 2020 /--- According to a new clinical trial, for patients with non-small cell lung cancer (NSCLC) that expresses PD-L1, atezolizumab treatment can lead to a longer total lifetime than chemotherapy.
published in the October 1, 2020 issue of the journal NEJM under the title "Atezolizumab For First-Line Treatment of PD-L1-Selected Patients with NSCLC."
the mechanism of atezolizumab, Atez, pictured from Clinical Cancer Research, 2017, doi:10.1158/1078-0432.CCR-16-1417.
Dr. Roy S. Herbst of Yale University School of Medicine and colleagues conducted an open-label Phase III randomized clinical trial involving 572 patients who did not receive chemotherapy and had PD-L1 expression of metastasis non-scale or scaly NSCLC.
patients were randomly assigned to ateju monotherapy (the artjudon anti-treatment group) or chemotherapy (the following chemotherapy group) in a 1:1 ratio.
the researchers found that among the 205 patients with the highest expression of PD-L1 EGFR and ALK wild tumors, the medium total survival of the Atju single anti-treatment group was higher than that of chemotherapy leaders (20.2 months for the former, 13.1 months for the latter and 0.59 for the risk of death).
Of all patients who could be assessed for safety, 90.2% of patients in the Atju monotherapy group and 94.7% in the chemotherapy group had adverse events, and 30.1% and 52.5% of the patients in the 3rd and 4th stage adverse events, respectively.
the total survival and non-progression survival of the Atju single anti-treatment group were better than those of the chemotherapy group in the subgroup of patients with higher mutation burden of blood type tumors.
the researchers wrote, "We found that in previously untreated patients with metastasis NSCLC with high expression PD-L1, the total lifetime of Artju monotherapy was longer than that of platinum combination chemotherapy."
" clinical study was funded by Roche/Genentek, the manufacturer of Attju monoantigen.
(bioon.com) Reference: 1.Roy S. Herbst et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. NEJM, 2020, doi:10.1056/NEJMoa1917346.2.Atezolizumab prolongs survival in NSCLC with PD-L1 expression.